达比加群酯，一种用于预防静脉血栓栓塞和中风的凝血酶抑制剂。

Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.

作者信息

Ieko Masahiro

机构信息

Health Sciences University of Hokkaido, Department of Internal Medicine, 1757-Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan.

出版信息

Curr Opin Investig Drugs. 2007 Sep;8(9):758-68.

PMID:17729188

Abstract

Dabigatran etexilate (BIBR-1048, Rendix), an orally active prodrug of the thrombin inhibitor dabigatran (BIBR-953ZW), is being developed by Boehringer Ingelheim Corp as a potential antithrombotic agent. By March 2003, the compound was in phase IIb/III trials for the prevention of deep vein thrombosis. By November 2005, a phase III trial had been initiated for the prevention of stroke and embolism due to atrial fibrillation and in May 2006 phase III trials for the prevention of secondary venous thromboembolism began. By July 2007, an EU filing for the drug had been made.

摘要

达比加群酯（BIBR-1048，Rendix），是凝血酶抑制剂达比加群（BIBR-953ZW）的口服活性前体药物，由勃林格殷格翰公司作为一种潜在的抗血栓药物进行研发。截至2003年3月，该化合物正处于预防深静脉血栓形成的IIb/III期试验阶段。截至2005年11月，已启动一项预防心房颤动所致中风和栓塞的III期试验，并且在2006年5月开始了预防继发性静脉血栓栓塞的III期试验。截至2007年7月，已向欧盟提交了该药物的申请。